# T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Source: https://onco.cc/trials/nct06343311/  
OnCo record `nct06343311` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of EB103 in non-Hodgkin lymphoma, hodgkin lymphoma and diffuse large B-cell lymphoma, run by Estrella Biopharma, Inc., now recruiting.

## Summary

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) is a phase 1/2 interventional study registered as NCT06343311 by Estrella Biopharma, Inc., with 21 participants planned, started 2024-06-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: EB103.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06343311
- Phase: 1/2
- Setting: An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of EB103 T-Cell Therapy in Adults With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)
- Sponsor: Estrella Biopharma, Inc.
- Enrolled: 21

## Sources

- ClinicalTrials.gov NCT06343311: https://clinicaltrials.gov/study/NCT06343311

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/nct06343311.json